Journal ArticleDOI
The 2001 Bethesda System: terminology for reporting results of cervical cytology.
Diane Solomon,Diane D. Davey,Robert J. Kurman,Marianne U. Prey,Stephen S. Raab,Mark E. Sherman,David C. Wilbur,Nancy A. Young +7 more
TLDR
The 2001 Bethesda System terminology reflects important advances in biological understanding of cervical neoplasia and cervical screening technology.Abstract:
ObjectivesThe Bethesda 2001 Workshop was convened to evaluate and update the 1991
Bethesda System terminology for reporting the results of cervical cytology.
A primary objective was to develop a new approach to broaden participation
in the consensus process.ParticipantsForum groups composed of 6 to 10 individuals were responsible for developing
recommendations for discussion at the workshop. Each forum group included
at least 1 cytopathologist, cytotechnologist, clinician, and international
representative to ensure a broad range of views and interests. More than 400
cytopathologists, cytotechnologists, histopathologists, family practitioners,
gynecologists, public health physicians, epidemiologists, patient advocates,
and attorneys participated in the workshop, which was convened by the National
Cancer Institute and cosponsored by 44 professional societies. More than 20
countries were represented.EvidenceLiterature review, expert opinion, and input from an Internet bulletin
board were all considered in developing recommendations. The strength of evidence
of the scientific data was considered of paramount importance.Consensus ProcessBethesda 2001 was a year-long iterative review process. An Internet
bulletin board was used for discussion of issues and drafts of recommendations.
More than 1000 comments were posted to the bulletin board over the course
of 6 months. The Bethesda Workshop, held April 30-May 2, 2001, was open to
the public. Postworkshop recommendations were posted on the bulletin board
for a last round of critical review prior to finalizing the terminology.ConclusionsBethesda 2001 was developed with broad participation in the consensus
process. The 2001 Bethesda System terminology reflects important advances
in biological understanding of cervical neoplasia and cervical screening technology.read more
Citations
More filters
Journal ArticleDOI
Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program.
Nicolas Wentzensen,Megan A. Clarke,Renee C. Bremer,Nancy Poitras,Diane Tokugawa,Patricia E. Goldhoff,Philip E. Castle,Mark Schiffman,Julie D. Kingery,Kiranjit K. Grewal,Alex Locke,Walter Kinney,Thomas Lorey +12 more
TL;DR: Triage of human papillomavirus–positive women with dual stain may lead to lower referral to undergo colposcopy with similar detection of precancerous lesions compared with cytologic screening, making cervical cancer screening more efficient.
Journal ArticleDOI
Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
Hormuzd A. Katki,Mark Schiffman,Philip E. Castle,Barbara Fetterman,Nancy Poitras,Thomas Lorey,Li C. Cheung,Tina Raine-Bennett,Julia C. Gage,Walter Kinney +9 more
TL;DR: Using the principle of “equal management of equal risks,” women testing HPV-positive/Pap-negative had a subsequent CIN 3+ risk consistent with risk thresholds for a 1-year return, but on returning in approximately 1 year, about one-half of women will be referred for colposcopy because of continued HPV positivity or Pap abnormality.
Journal ArticleDOI
A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial)
Gina Ogilvie,Gina Ogilvie,Dirk van Niekerk,Dirk van Niekerk,Mel Krajden,Ruth Elwood Martin,Thomas Ehlen,Kathy Ceballos,Kathy Ceballos,Stuart Peacock,Laurie Smith,Lisa Kan,Darrel Cook,Wendy Mei,Gavin Stuart,Eduardo L. Franco,Andrew J. Coldman +16 more
TL;DR: HPV-FOCAL is the first randomized trial in North America to examine hr-HPV testing as the primary screen for cervical cancer within a population-based cervical cancer screening program.
Journal Article
Epidemiology and natural history of genital human papillomavirus infection.
TL;DR: Phase 3 studies of a quadrivalent vaccine that protects against both high- and low-risk types of HPV demonstrated the vaccine to be 100% effective in preventing HPV type 16– and type 18–associated cervical disease, suggesting that these vaccines, if made widely available, will dramatically reduce the burden of HPV-related disease.
Journal ArticleDOI
The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer.
Philip E. Castle,Barbara Fetterman,J. Thomas Cox,Ruth Shaber,Nancy Poitras,Thomas Lorey,Walter Kinney +6 more
TL;DR: Human papillomavirus testing may be useful for triage for colposcopic referral for LSIL cytology in older women but not for ASC-H cytology at any age.
References
More filters
Journal ArticleDOI
Natural history of cervicovaginal papillomavirus infection in young women
TL;DR: An increased risk of HPV infection was significantly associated with younger age, Hispanic ethnicity, black race, an increased number of vaginal-sex partners, high frequencies of vaginal sex and alcohol consumption, anal sex, and certain characteristics of partners.
Journal ArticleDOI
Natural History of Cervicovaginal Papillomavirus Infection in Young Women Gyf Ho
TL;DR: The incidence of HPV infection in sexually active young college women is high and the short duration of most HPV infections in these women suggests that the associated cervical dysplasia should be managed conservatively.
Journal ArticleDOI
Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis
TL;DR: Modifications in host-cell genes, most likely engaged in the control of HPV gene expression in proliferating cells, emerge as important events in HPV-mediated carcinogenesis.
Journal ArticleDOI
2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities
TL;DR: Management of women with atypical squamous cells (ASC) depends on whether the Papanicolaou test is subcategorized as of undetermined significance (ASC-US) or as cannot exclude high-grade squamous intraepithelial lesion (HSIL) (asc-H).
Journal ArticleDOI
Comparison of Three Management Strategies for Patients With Atypical Squamous Cells of Undetermined Significance: Baseline Results From a Randomized Trial
TL;DR: HC 2 testing for cancer-associated HPV DNA is a viable option in the management of women with ASCUS and has greater sensitivity to detect CIN3 or above and specificity comparable to a single additional cytologic test indicating ASCUS or above.